Biogen Reports Q2 2026 Revenue of $2.74B, Growth Portfolio Surges 24% Led by Strong LEQEMBI and SKYCLARYS Performance
Biogen Inc. (NASDAQ: BIIB) released its second-quarter 2026 financial results, reporting revenue of USD 2.736...
Bayer Reports Q2 2026 Sales of EUR 10.87B, Driven by Strong Nubeqa and Kerendia Growth Despite Xarelto and Eylea Patent Expirations
Bayer AG (ETR: BAYN) released its financial results for the second quarter of 2026, reporting...
Takeda Reports Q1 FY2026 Revenue of JPY 1.22 Trillion, Outlines Growth Strategy Centered on Three Key Pipeline Assets
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) released its financial results for the first...
Leads Biolabs’ Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership
Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that Oblenio Bio, a NewCo jointly established...
Amgen Reports Q2 2026 Revenue of $10.05B, Driven by 26% Growth in Core Portfolio Despite Denosumab Decline
Amgen (NASDAQ: AMGN) released its financial results for the second quarter of 2026, reporting revenue...
Allergan Aesthetics’ BOTOX Cosmetic sBLA Accepted by FDA for Masseter Muscle Prominence, Poised to Become First Neurotoxin Indication
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), announced that the U.S. Food and Drug...
Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance
Curium Pharma, a private equity-backed radiopharmaceutical company, has agreed to acquire peer Lantheus Holdings (NASDAQ:...
Sino Biopharmaceutical’s BCL-2 Inhibitor TQB3909 Tablet Receives CDE Acceptance for CLL/SLL Treatment in Relapsed/Refractory Patients
Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary Chia Tai Tianqing Pharmaceutical (CTTQ)‘s New...
Haixi Pharma’s Oral nAMD Drug Candidate HX9428 Receives FDA Clearance for Phase 2 Trials, Offering Alternative to Intravitreal Injections
Fujian Haixi Pharmaceuticals Co., Ltd. (HKG: 2637) announced that the Investigational New Drug (IND) application...
Sanofi Secures European Commission Approval for MenQuadfi Pediatric Indication Extension to Infants from Six Weeks of Age
Sanofi (NASDAQ: SNY) announced that the European Commission (EC) has approved an extension of the...
Novo Nordisk Reports Q2 2026 Net Sales of DKK 78.5B, Driven by Strong Semaglutide Performance Despite Portfolio Restructuring
Novo Nordisk (NYSE: NVO) today released its financial results for the second quarter of 2026,...
Alphamab Oncology’s Anbenitamab NDA Accepted by China NMPA for HER2+ Breast Cancer Neoadjuvant Treatment, Granted Priority Review
Alphamab Oncology (HKG: 9966) announced that the New Drug Application (NDA) for Anbenitamab (trade name:...
Innovent Biologics Reports H1 2026 Revenue Exceeding RMB 8.2 Billion, Up 55% Year‑Over‑Year
Innovent Biologics (HKG: 1801) today announced its product revenue for the first half of 2026,...
AbbVie Reports 10.2% Revenue Growth in Q2 2026, Driven by Strong Immunology Performance
AbbVie (NYSE: ABBV) announced financial results for the second quarter (Q2) of 2026. Financial Performance...
WuXi AppTec Reports 38.9% Revenue Growth in H1 2026, Raises Full-Year Guidance
WuXi AppTec Co., Ltd. (SHA: 603259, HKG: 2359) released its first-half 2026 (H1’2026) financial results....
Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing
Alphamab Oncology (HKG: 9966) announced that it has entered into a licensing agreement with Pathos...
Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing
In May 2026, Hunan Zonsen PepLib Biotech Inc. successfully completed a Series C financing round...
CARsgen Therapeutics’ CT0596 Receives NMPA Clinical Approval for Relapsed/Refractory Multiple Myeloma
CARsgen Therapeutics (HKG: 2171) announced that CT0596 has received clinical approval from the National Medical...
InnoCare Pharma’s Orelabrutinib-Mesutoclax Combination Receives Breakthrough Therapy Designation for Marginal Zone Lymphoma
InnoCare Pharma Limited (HKG: 9969, SHA: 688428) announced that the combination regimen of orelabrutinib and...
Adlai Nortye’s AN4035 Receives Australian Regulatory Approvals for First-in-Class Pan-RAS(ON) ADC
Adlai Nortye (NASDAQ: ANL) announced that the company’s independently developed antibody-drug conjugate (ADC) AN4035, which...